688185.SS SHH
CanSino Biologics Inc.
1W: +28.7%
1M: +36.1%
3M: +96.0%
YTD: +56.9%
1Y: +22.6%
3Y: +27.1%
5Y: -84.7%
¥102.64 ($15.30)
+17.11 (+20.00%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$1.1B
+26.2% ▲
5Y CAGR: +112.1%
Gross Profit
$1.1B
+83.0% ▲
5Y CAGR: +153.7%
Operating Income
$24M
+106.4% ▲
Net Income
$28M
+107.4% ▲
EPS (Diluted)
$0.11
+107.2% ▲
EBITDA
$207M
+252.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $1.0B | $357M | $846M | $1.1B |
| YoY Growth | +17174.8% | -75.9% | -65.5% | +137.0% | +26.2% |
| Cost of Revenue | $1.3B | $1.2B | $801M | $263M | $0 |
| Gross Profit | $3.0B | -$184M | -$444M | $584M | $1.1B |
| Gross Margin | 69.8% | -17.8% | -124.3% | 69.0% | 100.0% |
| R&D Expenses | $879M | $778M | $638M | $416M | $0 |
| SG&A Expenses | $327M | $535M | $640M | $548M | $0 |
| Operating Expenses | $1.1B | $997M | $1.5B | $959M | $1.0B |
| Operating Income | $1.9B | -$1.2B | -$1.9B | -$375M | $24M |
| Operating Margin | 45.1% | -114.1% | -542.3% | -44.3% | 2.2% |
| Interest Expense | $20M | $42M | $64M | $60M | $0 |
| Income Before Tax | $1.9B | -$1.2B | -$2.0B | -$381M | $22M |
| Tax Expense | $30M | -$219M | -$12M | $2M | -$6M |
| Net Income | $1.9B | -$909M | -$1.5B | -$379M | $28M |
| Net Margin | 44.5% | -87.9% | -415.2% | -44.8% | 2.6% |
| EPS (Diluted) | $7.74 | $-3.69 | $-6.01 | $-1.53 | $0.11 |
| EBITDA | $1.8B | -$1.3B | -$1.5B | -$194M | $207M |
| Shares Outstanding | 247M | 247M | 247M | 248M | 253M |